Prevalence of Microspirometry-Detected Chronic Obstructive Pulmonary Disease in Two European Cohorts of Patients Hospitalised for Acute Myocardial Infarction
Heart and lung diseases collide, COPD ups post-MI risks; ICS could protect select patients with high eosinophils.
Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease (CVD) and shares risk factors such as smoking, ageing and systemic inflammation.1 2 Following myocardial infarction (MI), mortality and heart failure are around 30–35% higher in those with COPD compared with those without.3 Conversely, CVD can worsen COPD outcomes by impairing heart and lung function and exacerbating respiratory symptoms. Inhaled pharmacotherapy in COPD includes long-acting ß2 receptor agonists (LABA), long-acting muscarinic antagonists (LAMA) and inhaled corticosteroids (ICS). ICS have been suggested to have beneficial effects on cardiovascular risk and all-cause mortality, especially in patients with a high blood eosinophil count.4 5
Click here to access the article.